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Abstract
BACKGROUND: Sarcomas comprise 1% of malignant tumors in adults but represent a significant diagnostic and therapeutic 
challenge. Molecular imaging with 18FDG PET/CT is a powerful modality in oncology. Its use for initial assessment, evaluation 
of response to therapy and recurrent disease in most tumors is essential for therapeutic decisions. Its indication in sarcomas is 
still controversial. One of the indications for PET/CT in sarcomas is detection of recurrences. Nowadays magnetic resonance 
tomography (MRT) has a crucial role in identification of local recurrences in soft tissue and bone sarcoma. 18FDG-PET/CT may 
serve as a complementary method. Dual time point imaging (DTPI) has been studied for most tumors as a method for differen-
tiating benign from malignant lesions. There is limited data on DTPI in sarcomas. Therefore we studied prospectively patients 
with suspected local recurrences in the treated area and used DTPI as a method for differentiating benign from malignant tissue.
The aim of this study was to evaluate the ability of dual-time point PET/CT to enhance sensitivity, specificity, PPV, NPV and 
accuracy of 18FDG PET/CT in high grade and low grade sarcomas. 
MATERIAL AND METHODS: We conducted a dual-time PET/CT in 15 patients with suspected locally recurrent disease. The 
delayed scan was conducted on the 120th min in the suspected region. The interpretation of PET/CT was made both upon CT 
scan and metabolic scans. The percentage change over time per lesion was calculated (%DSUV). The increase in SUVmax 
with %DSUV > 10% in the late scanning was considered as indicative for malignancy. We assessed the sensitivity, specificity, 
accuracy, positive and negative predicting value of the interpretation of PET/CT at 60 min and 120 min. All of the patients were 
followed up for a period of 1–3 years after our examination, either with histologic results, or with an MRT scans.
RESULTS: The received sensitivity, specificity and accuracy of 18FDG PET/CT interpretation at 120 min in high grade sarcomas 
were respectively 100%, 80% and 89%. By comparison, in low grade tumors at 120 min scan, these parameters were 50%, 
75% and 66%. 
CONCLUSION: These preliminary data suggests that dual-time imaging in sarcomas improves sensitivity and accuracy in 
identification of local recurrent disease in high grade sarcomas and have limited role in low grade sarcomas. Further research 
is necessary to confirm these results.
KEY words: soft tissue, bone sarcomas, dual- time-point imaging, 18FDG-PET/CT, local recurrence
Nuclear Med Rev 2016; 19, 1: 22–27
Background
Sarcomas comprise 1% of malignant tumors in adults. They 
are a large heterogeneous group of entities with different biologi-
cal behavior and the clinical diagnosis of such lesions can be very 
difficult. Molecular imaging with 18FDG PET/CT (fluoro-deoxyglu-
cose-positron emission tomography with computed tomography) 
is a powerful modality in oncology. Its use for initial assessment, 
staging, restaging, evaluation of response to therapy and recur-
rent disease in most tumors is essential for therapeutic decisions. 
It has been utilized as an alternative pretreatment imaging method 
for both soft tissue and bone sarcomas [1, 2]. Another use of 
18FDG-PET/CT is evaluation of response to chemotherapy. Definitive 
treatment of sarcoma is surgical resection. However, after surgical 
23www.nmr.viamedica.pl
Zhivka Dancheva et al., Dual-time point 18FDG-PET/CT imaging in assessing local recurrent disease
Original
removal, 40% to 60% of the patients will develop local or distant 
recurrence. Detection of local recurrent disease is still a contro-
versial indication for PET/CT in sarcomas. Nowadays magnetic 
resonance tomography (MRT) has a crucial role in identification of 
local recurrences in soft tissue and bone sarcoma. 18FDG-PET/CT 
may serve as a complementary method, searching for metabolic 
activity in treated regions. The accumulation and metabolism of 
18FDG is dependent on many factors. Glucose-6-phosphatase, 
hexokinase and GLUT transporters appear to be most impor-
tant. Dual-time-point imaging (DTPI) has been studied for most 
tumors as a method for differentiating benign from malignant 
lesions. There is limited data on DTPI in sarcomas. Therefore we 
studied patients with suspected local recurrences in the treated 
area prospectively using DTPI as a method for differentiating post 
treatment inflammation vs. local malignancy.
Our aim was to study the ability of dual-time-point PET/CT to 
enhance sensitivity, specificity, PPV, NPV and accuracy of 18FDG 
PET/CT in high grade and low grade sarcomas.
Materials and methods
Patients
For a period of six years (2009–2015), we examined 15 pa-
tients with suspected local recurrent disease. The patients were two 
women and thirteen men, from 27 to 78 years old. The final verifica-
tion was made by histologic results either with MRT scans and all 
of them were followed up clinically for a period of 1–6 years after 
our examination.
Inclusion parameters
All of the patients had previously locally treated sarcoma and 
imaging findings suspicious for residual or recurrent disease from 
other imaging modalities. We performed 120 min scan in those 
patients who have been treated locally for sarcoma (excision, 
radiotherapy or alloplastic joint replacement) and had difficult for 
interpretation PET/CT 60 min scans. We conducted a second scan 
if the local SUVmax was 2.0 or higher but was not sufficient to be 
interpreted as a local recurrent disease. We included patients with 
soft tissue and bone sarcomas of different grades. The number of 
various histological subtypes of sarcomas according to the AJCC 
classification and their grading are summarized in Table 1. There 
were 8 patients with high grade tumors and 6 patients with low 
grade tumors.
Table 1. Type and grade of sarcomas in the examined patients
Type of sarcoma n Low grade (n) High grade (n)
Hondrosarcoma 1 1
Liposarcoma 7 3 4
Ewing sarcoma 1 1
Malignant fibrous histiocytoma 1 1
Leiomyosarcoma 2 2
Sinovial sarcoma 1 1
Fibrosarcoma 1 1
Osteosarcoma 1 1  
Methods
The examination was held on Gemini TF PET/CT, Philips, 
equipped with 16 slice CT. We performed low-dose CT. The PET/CT 
scan was held at two time points, at 60 min and at 120 min. The early 
scan was obtained from the skull base to mid-thigh, whereas the 
second scan was acquired only for the area of interest. 
PET/CT imaging was performed in patients three months after 
radiotherapy and one month after surgery or chemotherapy. All 
of the patients fasted for at least 6 h before the examination to 
ensure standardized glucose metabolism. At the time of 18FDG 
administration, fasting plasma glucose values were lower than 
150 mg/dL in all patients. Depending on the patients’ weight, a dose 
of 185–555 mBq was administrated through a catheter inserted 
into an antecubital vein.
Interpretation
The interpretation of PET/CT was made upon CT scan, meta-
bolic scan and fused scans. We used SUVmax-based quantification 
for differentiation of benign from malignant lesions. Studies have 
demonstrated significant variability of SUVmax values in test-retest 
measurements, ranging from 6 to 10 percent [3] with increase in 
variability with higher SUVmax values. The percentage change over 
time per lesion was calculated (%DSUV). Zuang et al. published 
similar results in DTPI with PET/CT in a variety of tumors. The 
average SUV of the lesions in known cancer patients increased 
from 3.96 at the first time point to 4.72 at the second time point 
(+19.2% ± 9.6%; n = 31; P < 0.001) [4]. As reproducibility of SU-
Vmax is subject to significant variation, we accepted as indicative 
for malignancy the increase in SUVmax with %DSUV > 10% in the 
late scanning. The sensitivity, specificity, accuracy; PPV and NPV 
were estimated in all of the patients and in the two groups — with 
low and with high grade tumors.
Results
We assessed the sensitivity, specificity, positive (PPV), nega-
tive predictive value (NPV) and accuracy in all of the cases at 60 
and 120 min and separately in high grade and low grade sarco-
mas at 120 min. Results are listed in Tables 2 and 3. The evaluation 
was made for PET/CT interpretations at 60 min and at 120 min.
True positive results at 120 min were obtained in 3 pa-
tients with high grade tumors and in one patient with low 
grade tumor (Figure 1). True negative results were obtained in 
Table 2. True positive, true negative, false positive and false negative 
results in patients at 60 min and 120 min, and in high and low grade 
sarcomas at 120 min
All patients High grade  
sarcomas
Low grade  
sarcomas
 60 min 120 min 120 min 120 min
TP 2 4 3 1
TN 5 8 5 3
FP 5 2 1 1
FN 3 1 0 1
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5 patients with high grade tumors and 3 patients with low grade 
tumors (Figure 2).
The 120 min scan was not helpful to reveal two of the false 
positives at 60 min PET/CT scan. (Figure 3 and 4) These two cases, 
one in high grade and one in low grade group, significantly raised 
their SUVmax at 120 min. Both of the cases were with chronic 
osteomyelitis after local treatment — one after the tumor excision 
and the other after excision and radiotherapy. 
There were three cases of false negative PET/CT interpreta-
tions for recurrent disease at 60 min scan because of low to medium 
SUVmax 2.8–3.1. The three of them became positive at the 120 min 
scan with SUVmax increase of 39–42%. All of them were high grade 
tumors. There was only one case with low grade tumor and false 
negative result at 120 min. The 60 min scan was correctly interpreted 
as positive. It was with inhomogeneous uptake in the treated area 
and SUVmax 3.1 at 60 min scan suspicious for recurrent disease. 
SUVmax did not increase at 120 min. and was interpreted falsely 
as negative. That patient had many local recurrences followed 
by local excisions. After the histology result it was proved to be 
tumor tissue.
The total sensitivity of the 60 min PET/CT scan for determina-
tion of a recurrent disease was only 40%. By the 120 min scan 
methodology, we managed to determine the recurrent disease 
in all of the patients with high grade sarcomas and only in 50% 
in those with low grade tumors. The specificity of the method 
was better for high grade sarcomas 83%. The specificity was re-
duced because of the false positive results in two patients with 
chronic osteomyelitis.
The PPV was better in patients with high grade sarco-
mas — 75% vs 50% in low grade sarcomas. The NPV was better 
in the late study; in high grade sarcomas it was 100%, revealing 
all of the patients without disease. 
Accuracy in identifying recurrent disease in high grade sarco-
mas, using the dual-time-point PET/CT scan was 89%, vs. 67% in 
low grade sarcomas.
Table 3. Results of the sensitivity, specificity, PPV, NPV and accuracy 
in all of the patients and in two groups of patients: with high grade and 
with low grade sarcomas
 All patients High grade 
sarcomas
Low grade 
sarcomas
 60 min 120 min 120 min 120 min
Sensitivity 40% 80% 100% 50%
Specificity 50% 80% 83% 75%
PPV 29% 89% 75% 50%
NPV 63% 89% 100% 75%
Accuracy 47% 80% 89% 67%
Figure 1. A patient with MFH of the right forearm: A. Equivocal 60 min  
scan with SUVmax in the operation area of 3.1; B. The 120 min 
scan was positive with SUVmax 4.5, later confirmed by histology as 
a recurrent tumor
Figure 3. A patient with low grade fibrosarcoma three months after 
tumor excision and fibular resection. The 120 min scan showed 27.8% 
increase in activity in the primary tumor area. The result was proved 
false positive, as the patient had no tumor tissue but only inflammatory 
cells
A
A
B
B
Figure 2. A patient with high grade chondrosarcoma five years after 
chemotherapy and tumor excision with alloplastic replacement of  
the right knee joint; A. (Early scan) Although the high SUVmax at  
60 min scan — 6.5, at the late scan (B) this value did not change — 
true negative result. This person was followed up for 5 years without 
recurrent disease
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Discussion
PET/CT was studied as a helpful instrument for initial assess-
ment in sarcoma, but also for evaluation of response to therapy [5] 
and detection of recurrences in STS (soft tissue sarcoma) and BS 
(bone sarcoma). During the initial workup of sarcomas, MRT pro-
vides better description and definition of the local extent of the tumor. 
PET/CT has been found to be useful in prognostication, grading and 
assessing response to chemotherapy [2, 6, 7]. SUVmax has been 
shown to correlate with tumor grade and progression [8, 9]. Lodge 
et al. [10] noted that in high grade sarcomas, the maximal 18FDG 
uptake is reached at 4 h whereas benign lesions achieve such 
values within 30 min. False negative findings were often found in 
low grade sarcomas.
We used SUVmax-based quantification for revealing malignant 
lesions in the treated area of the primary tumor. Studies have 
demonstrated significant variability of SUVmax values in test-retest 
measurements, ranging from 6 to 10 percent [3, 4] with increase 
in variability with higher SUVmax values. Evaluating the DTPI value 
in lung nodules, Matthies et al concluded that dual-time-point 
scanning with a threshold value of 10% increase between scan 
1 and scan 2 reached a sensitivity of 100% with a specificity of 
89% [11]. We also accepted that a change of SUVmax higher or 
equal to 10% was significant for interpretation of malignancy at 
the 120 min scan.
The logic behind delayed 18FDG PET/CT imaging is based on 
the known fact that most types of malignant cells have significantly 
increased ratios of hexokinase to glucose-6-phosphatase activi-
ties, which allow 18F-deoxyglucose-6-phosphate to accumulate to 
a much higher level over time than in the normal cells. There is in-
sufficient data on the role of PET/CT in patients with suspected 
recurrent sarcoma after local therapy. In rhabdomyosarcoma 
PET/CT was found useful for detecting recurrent disease in treated 
patients. [12] It may be useful for initial staging too because of the 
possibility of nodal metastases and unknown distant metastases. 
In these patients management intent may change from curative to 
palliative, thereby sparing patients the morbidity associated with 
non-beneficial aggressive treatment. A few articles are focused 
on the performance of DTPI and delayed time-point imaging in 
assessing residual/recurrent lesions after therapy in breast cancer 
and in head and neck cancer [13, 14]. PET/CT should avoid un-
necessary biopsy through ruling out residual or recurrent active 
disease. Patient outcomes may be improved through reduced 
treatment morbidity. 
The major value of DTPI is the increased sensitivity due to 
continued clearance of background activity and continued 18FDG 
accumulation in malignant lesions. In order to homogenize the 
groups of patients, we divided them into two groups — with low 
and high grade sarcomas. In our investigation, we had only one 
false negative result at 120 min in low grade sarcoma, and no false 
negatives in high grade sarcomas. All of the false negative high 
grade sarcomas at 60 min turned to true positives at 120 min scan, 
which was the most important achievement in our investigation. 
The yielded sensitivity at 120 min increased from 40% to 80% for all 
cases. In high grade sarcomas group we managed to reach 100% 
sensitivity at 120 min, which was significantly better result than in the 
low grade sarcomas group only 50% (p = 0.034). Tumor heteroge-
neity, the small size of the recurrent tumor and low grade tumor (low 
metabolic activity) may contribute to variable performance of DTPI 
18FDG PET/CT imaging [15, 16]. Tumor heterogeneity is based on 
variations in tumor cells (tumor genotype, differentiation) or in the 
environment (stromal matrix and tumor location, tissue vascularity 
and tumor size, and immune status, etc.). Tumor heterogeneity in 
sarcomas is very often. In our cases the only false negative result 
at 120 min was a patient with many recurrent episodes and treat-
ments. He had a low grade tumor. This suggested the limited value 
of DTPI for the characterization of non-18FDG-avid tumors which 
was reported also in pancreatic cancer with low SUVmax [17].
Dual-time-point imaging has been used to increase specificity 
of 18FDG PET for discriminating benign from malignant lesions. That 
is exceptionally important in the treated area, where operations and 
local radiotherapy may cause inflammatory comp-point 18FDG-PET 
imaging in this regard, and the technique has been studied in a wide 
variety of malignancies, including those of head and neck [18], lung 
[11], breast [19–21], gallbladder [22], cervix [23] and glioma [24]. 
In all of them authors concluded that delayed 18FDG-PET imaging 
is more helpful than early scans for evaluating malignant lesions. 
However, exceptions exist, and some studies have demonstrated 
significant overlap of 18FDG uptake patterns between benign and 
malignant lesions on delayed time-point images. In many of these 
studies, dual time point PET improved both the sensitivity and the 
specificity of PET/CT. This can be explained by two factors: while 
continuing increased uptake in the malignant lesions allows dif-
ferentiation from benign lesions with higher specificity, increased 
Figure 4. A patient with Ewing sarcoma 18 years after operation and radiotherapy. A fracture of the left iliac bone is seen. The SUVmax at 120 min 
scan increased by 14.1% — a false positive result, due to chronic osteomyelitis
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lesion-to-background leads to higher sensitivity with this method. In 
the majority of normal tissues (the blood pool, liver, spleen, lungs, 
pancreas, inguinal nodes, and skeletal muscles), 18FDG uptake 
decreases significantly from 1 to 3 h after radiotracer injection, 
although SUV remains stable in some tissues (parotid gland, thyroid 
gland, and prostate gland) and increases in other tissues (myocar-
dium and bone marrow) [25].
The specificity of this method in our study was increase 
from 50% in all cases to 80% at 120 min imaging. In high grade 
tumors group our study reached specificity 83% at 120 min scan 
(60 min scan specificity in this group was 67%). The specificity in 
low grade tumors group also was better at 120 min scan (75% 
vs 25% in early scan). We could not reduce two of the false posi-
tive results with chronic post treatment inflammation. All of the true 
negatives in both groups at 60 min scan remained TN at 120 min 
scan. Our method was useful to reveal three of the true negatives: 
two cases after tumor excision and one with alloplastic joint and 
high SUVmax at 60 min scan. At the late scan the SUVmax did not 
change or lowered, with 19% in a low grade liposarcoma.
There are numerous reports in the literature of false-positive 
findings on 18FDG PET imaging due to granulomas or active 
inflammation. The granulomas may arise many years after the 
initial trauma or procedure in the form of tumor-like soft-tissue 
masses [26–28]. Multiple studies have indicated that lesions of 
active inflammation and infection may have higher 18FDG activity 
on DTPI, similar to that in malignant lesions, thus resulting in sub-
optimal diagnostic performance of DTPI [29–31]. There were two 
false positive cases among our patients, both with osteomyelitis, 
which remained false positive at late scans. Respectively, their 
SUVmax values were: SUVmax (60 min) 3,6/SUVmax (120) 4.6 and 
SUVmax (60 min) 6,4/SUVmax (120) 7.3. This was a change in the 
SUVmax with respectively 27.8% and 14.1%. This results in future 
indicates the need for more careful selection of the patients for 
PET/CT scan and necessity of histologic confirmation after PET/CT 
positive findings. On the other hand, our methodology was able to 
resolve the problem with the metabolic active lesions at 60 min scan 
in three cases with active inflammation. One of the cases was a pa-
tient after alloplastic joint replacement with SUVmax (60 min) 6.5. 
This value stayed the same at 120 min scan and was interpreted 
as a negative for recurrent disease, lately confirmed by 3-year follow 
up. Another case was a patient with low grade tumor excision in 
whom SUVmax (60 min) was 4.2. After the late scan it decreased 
by 19% — SUVmax (120 min) 3.4. The third case also had a stable 
SUVmax value at the early and delayed scan (SUVmax 2.9) and 
was interpreted as negative after the 120 min scan. It was a patient 
with a high grade tumor. All of these data showed that increased 
18FDG uptake on delayed time-point images should not be used 
as the sole criterion in interpreting 18FDG PET studies. Correlation 
with other imaging findings, as well as the patient’s history, should 
also be taken into consideration. And the late scans could improve 
the specificity both in high grade and low grade sarcomas.
The PPV was very low at 60 min scan for all patients — 29%, 
which was because of too many complicated cases with false positive 
scans at that time point. Our methodology managed to increase the 
PPV — from 29% to 67% at 120 min scan, resolving 3 of 5 cases with 
false positive and all three false negative 60 min scans (changing the 
classification into true positives). In high grade sarcomas group the 
gained PPV was 75% vs. 50% in low grade tumors group. 
In different studies the NPV of 18FDG-PET/CT in revealing recur-
rent disease varies from 75 to 100%. Other studies did not separate 
the subjects into groups according to their tumor differentiation. In 
our investigation NPV was 100% in high grade sarcomas at 120 min 
scan compared with 63% at 60 min scan and 89% at 120 min scan 
in all patients. In low grade tumors the NPV was 75%. At 120 min 
scan three of the false positive subjects turned into true negatives, 
because the SUVmax value did not change or got lower. Other false 
positives at 60 min were two cases with inflammatory complica-
tions. Excluding those two subjects, our methodology was useful 
for revealing all of the patients without recurrent disease. 
Accuracy of the method also improved the values in the 
whole group — 47% at 60 min scans and 80% at 120 min scans. 
It was again better, although not significantly, in high grade tu-
mors group 89% vs. 67% in low grade tumors.
Conclusion
Most malignant (and some inflammatory) lesions have in-
creased 18FDG uptake on delayed time-point images. Our study 
suggests that dual- time 18FDG-PET/CT in sarcomas might have 
a valuable role in detecting local recurrent disease in high grade 
sarcomas, as the sensitivity of the method gained significantly 
better results than in low grade sarcomas group at the same time 
point. The specificity, PPV and NPV are better in patients without 
late radiation and surgery complications. Accuracy was also better 
in high grade sarcomas. These results suggest that we must care-
fully select the patients for late PET/CT scan and have thorough 
information about current inflammations in the treated area.
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